By VETTAPHARMA reporter – Derek Roche: Novartis, a global innovative medicines company, announced plans to establish a 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, set to become operational in 2028 — expanding its RLT manufacturing footprint in the United States.
Key details from the press release:
- The Denton site will be Novartis’ fifth RLT manufacturing facility in the US and the company’s first manufacturing facility in Texas.
- This project is part of Novartis’ broader $23 billion investment in US operations.
- Construction is expected to begin this year, with the facility fully operational by 2028.
- The plant is projected to create jobs in bioengineering, advanced manufacturing, quality, and operations, supporting local economic growth in Denton and nearby communities.
- The new site will serve patients in the Southern US and boost capacity as RLT expands into earlier treatment lines and additional tumor types.
- It will join a comprehensive US RLT network that includes existing manufacturing sites in New Jersey, Indiana, and California, as well as a planned facility in Florida.
Leadership Perspectives:
- Novartis CEO Vas Narasimhan emphasized that RLT “has the potential to revolutionize cancer care” and that the additional US manufacturing capacity will help the company meet growing demand with greater speed and precision.
- Texas Governor Greg Abbott praised the investment, noting the state’s status as a biotech hub and the creation of “good-paying jobs in bioengineering, advanced manufacturing, and more.”
About Radioligand Therapy:
Radioligand therapy is a precision oncology approach that delivers radiation directly to tumor cells via a tumor-targeting molecule linked to a radioisotope, potentially improving outcomes while limiting damage to healthy tissue.
